Use of combined hormonal contraception and stroke: A case-control study of the impact of migraine type and estrogen dose on ischemic stroke risk.
Pelin BaturMeng YaoJulia BucklanPayal SoniAarushi SunejaRuth FarrellMaryann MaysPublished in: Headache (2023)
Overall stroke risk in our cohort of CHC users was low. When CHCs are used in those with migraine, formulations containing ≤30 μg EE are preferred. Shared decision-making should include discussions about ischemic stroke risks in patients with migraine, even those without aura.